Radiopharmaceutical · Acts on L-type amino acid transporter 1 (SLC7A5) · developed by Heron Neutron Medical
F18 FBPA (4-borono-2-[18F]fluoro-L-phenylalanine) is a radiolabeled phenylalanine analog used in positron emission tomography. Its uptake is mainly facilitated by the L-type amino acid transporter 1 (LAT1), which is commonly overexpressed in malignant tumors, allowing preferential accumulation in tumor tissue for tumor imaging in solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07691775 | Phase 1/2 | Solid Tumor | Recruiting | HRTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid Tumor
Updated Oct 18, 2026. Something wrong or missing? Report it on the HRTX page.
See HRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HRTX catalysts and pipeline →